Send to

Choose Destination
Int J Cancer. 2018 Jan 1;142(1):165-175. doi: 10.1002/ijc.31034. Epub 2017 Sep 18.

Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients.

Author information

Department of Surgical Oncology, Erasmus MC Cancer Institute, 3075 EA, Rotterdam, The Netherlands.
Department of Research, Netherlands Comprehensive Cancer Organisation, 3511 DT, Utrecht, The Netherlands.
Department of Health Technology & Services Research, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, 7500 EA, Enschede, The Netherlands.
Department of Surgery, Maxima Medical Center, 5504 DB, Veldhoven, The Netherlands.
Department of Surgical Oncology, Canisius Wilhelmina Hospital, 6532 SZ, Nijmegen, The Netherlands.
Department of Radiation Oncology, Institut Curie, 26, Rue d'Ulm, 75248 Paris cedex 05, France.


This large population-based study compared breast-conserving surgery with radiation therapy (BCT) with mastectomy on (long-term) breast cancer-specific (BCSS) and overall survival (OS), and investigated the influence of several prognostic factors. Patients with primary T1-2N0-2M0 breast cancer, diagnosed between 1999 and 2012, were selected from the Netherlands Cancer Registry. We investigated the 1999-2005 (long-term outcome) and the 2006-2012 cohort (contemporary adjuvant systemic therapy). Cause of death was derived from the Statistics Netherlands (CBS). Multivariable analyses, per time cohort, were performed in T1-2N0-2, and separately in T1-2N0-1 and T1-2N2 stages. The T1-2N0-1 stages were further stratified for age, hormonal receptor and HER2 status, adjuvant systemic therapy and comorbidity. In total, 129,692 patients were included. In the 1999-2005 cohort, better BCSS and OS for BCT than mastectomy was seen in all subgroups, except in patients < 40 years with T1-2N0-1 stage. In the 2006-2012 cohort, superior BCSS and OS were found for T1-2N0-1, but not for T1-2N2. Subgroup analyses for T1-2N0-1 showed superior BCSS and OS for BCT in patients >50 years, not treated with chemotherapy and with comorbidity. Both treatments led to similar BCSS in patients <50 years, without comorbidity and those treated with chemotherapy. Although confounding by severity and residual confounding cannot be excluded, this study showed better long-term BCSS for BCT than mastectomy. Even with more contemporary diagnostics and therapies we identified several subgroups that may benefit from BCT. Our results support the hypothesis that BCT might be preferred in most breast cancer patients when both treatments are suitable.


breast cancer; breast cancer-specific survival; breast conserving therapy; comorbidity; mastectomy; prognostic factors; radiation therapy

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center